Not Just for Diabetes: The Next Frontier for GLP-1 Agonists.
Where this comes from
- Record sourced from PubMed, PMID 42624784.
- Also identified by DOI 10.3122/jabfm.2025.250473R1.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
A commonly used GLP-1 agonist, semaglutide, reduces the risk of adverse cardiovascular outcomes in non-diabetic individuals with obesity and pre-existing cardiovascular disease.
Medical subject headings
- Glucagon-Like Peptides
- Obesity
- Cardiovascular Diseases
- Hypoglycemic Agents
- Glucagon-Like Peptide 1
- Diabetes Mellitus, Type 2